The significance of this in layman's terms: We will now have enough data that will satisfy Big Pharma to cut a deal .
If its a licensing partnership just for HerVaxx , based on how superior it is to anything else out there, its probably in the vicinity of US$1.5_2billion, in face value fees plus 15% of all future sales... That equates to approx 30_40c in special dividend distribution of the licensing fees, part up front, the balance as further steps taken. And allows the company to retain approx Us$200 million in working capital to fully fund additional vaccine development in the pre clinical / mimitope platform.
No brainer to sit and hold tight.
IMU Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
